4D Molecular Therapeutics

FDMT

Market cap $318M

Overview Fund Activity

6.80 USD

-0.01

0.15%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

6.70

-0.10

1.47%

1 day

-0.15%

5 days

-2.3%

1 month

-6.34%

3 months

55.61%

6 months

62.68%

Year to date

16.64%

1 year

-58.74%

5 years

-83.21%

10 years

-83.21%

About: 4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Employees: 227

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

16% more call options, than puts

Call options by funds: $171K | Put options by funds: $147K

7% more capital invested

Capital invested by funds: $141M [Q1] → $151M (+$10.1M) [Q2]

8% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 40

4% less funds holding

Funds holding: 124 [Q1] → 119 (-5) [Q2]

5.85% less ownership

Funds ownership: 93.06% [Q1] → 87.21% (-5.85%) [Q2]

24% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 21

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$25

268% upside

Avg. target

$32

363% upside

High target

$38

459% upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

Roth Capital Salveen Richter	$38	Buy Maintained	12 Aug 2025
Chardan Capital Geulah Livshits	$25	Buy Maintained	12 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about FDMT published over the past 30 days

4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on September 9, 2025, the compensation committee of the Company's board of directors granted four new non-executive employees 40,900 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, which was approved by the Company's board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

4DMT Announces New Employment Inducement Grants

4D Molecular Therapeutics, Inc. (FDMT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:50 PM EDT Company Participants David Kirn - Co-Founder, CEO & Director Christopher Simms - Chief Commercial Officer Conference Call Participants Judah Frommer - Morgan Stanley, Research Division Presentation Judah Frommer Equity Analyst To this session of the Morgan Stanley Global Healthcare Conference. I'm excited to welcome the team from 4D Molecular Therapeutics.

4D Molecular Therapeutics, Inc. (FDMT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness

Julie Clark, M.D., promoted to Chief Medical Officer Liansheng Zhu, Ph.D.

4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness

4DMT to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in fireside chats at upcoming investor conferences in September. Members of the management team will also be available for one-on-one meetings.

4DMT to Participate in Upcoming Investor Conferences

4DMT Announces New Employment Inducement Grants

EMERYVILLE, Calif., Aug. 15, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on August 12, 2025, the compensation committee of the Company's board of directors granted three new non-executive employees 58,900 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, which was approved by the Company's board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

4DMT Announces New Employment Inducement Grants

Zacks Investment Research

4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates

4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to a loss of $0.63 per share a year ago.

4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates

4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported Q2 2025 financial results, provided operational highlights and outlined expected upcoming milestones.

4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

EMERYVILLE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in a fireside chat at the H.C.

4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

These 3 health tech stocks spiked 37% in a day; Time to buy?

While the broader stock market suffered steep losses on Friday amid trade policy shifts and troubling economic data, select health technology equities stood out.

These 3 health tech stocks spiked 37% in a day; Time to buy?

4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study

Shares of 4D Molecular Therapeutics FDMT are currently up over 20.6% after the company released positive results from its Spectra trial.

4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study

See News Rankings

Charts implemented using Lightweight Charts™